ASHLAND GLOBAL 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Ashland reported third-quarter sales of $497 million, up 7% year over year, driven by 6% volume growth across all business units, modest 1% pricing improvement, and 1% FX benefit. Adjusted EBITDA was $109 million versus $113 million last year, with margin at 21.9% versus 24.4%, pressured by earlier production issues and normalized incentive compensation. Adjusted EPS was $1.20 versus $1.40. Free cash flow remained strong at $103 million, with conversion above 90%, helped by nearly $80 million of year-to-date inventory reduction. Net leverage improved to 2.4x and liquidity was $936 million.

Company Outlook & Strategy: Management reaffirmed fiscal 2026 sales guidance of $1.835 billion to $1.870 billion and adjusted EBITDA guidance of $385 million to $400 million. Adjusted EPS outlook was trimmed to low- to mid-single-digit growth from mid- to high-single-digit due to a higher tax rate from discrete items. Management expects a further step-up in Q4 profitability as pricing realization continues and operations improve. Strategic priorities remain Execute, Globalize, and Innovate, with both Globalize and Innovate already at or above full-year targets through nine months. Management emphasized disciplined pricing, margin recovery, and continued investment in higher-value technologies.

Key Industry Trends: Demand remained healthy across consumer-focused and pharma-related end markets, while industrial markets were more mixed but stabilizing. Pharma showed resilient demand, benefiting from GLP-1-related growth, injectable demand, and formulation complexity. Personal care continued to benefit from innovation adoption and reformulation trends. Coatings and construction markets remained soft in some regions, especially North America and Europe, though share gains and innovation improved performance. EV battery and energy storage demand supported intermediate sales through NMP demand.

Operational Highlights: Life Sciences sales rose 11% to $180 million, with pharma volume growth for the fifth consecutive quarter and strong momentum in high-purity excipients and injectables; Ashland also broke ground on a new tablet coating facility in India. Personal Care sales rose 5% to $155 million, with strong growth in biofunctional actives, microbial protection, and care ingredients; the company commissioned a new microbial protection facility in Europe and achieved first industrial production of multifunctional starch. Specialty Additives sales increased 4% to $136 million, aided by share gains and pricing in coatings and performance specialties, while Hopewell turnaround work and broader manufacturing optimization continued. Intermediates sales rose 12% to $37 million on stronger merchant demand, though EBITDA declined due to lower tax credit benefits. Cost savings from VP&D optimization and small plant consolidation are expected to total about $15 million this fiscal year, and management said pricing actions are now covering inflation.

Challenges & Risks: Profitability remains constrained by earlier production rate issues, especially at Hopewell, and management said improvements will flow through gradually over the next several quarters. Specialty Additives still faces weak construction and energy/resource demand, particularly in North America and Europe. Intermediates remain exposed to volatility in NMP and broader BDO chain conditions, and management was cautious on near-term demand. Nutrition-related new wins are arriving slower than expected, and market recovery in some end markets, especially construction, remains uncertain. The company also noted a higher tax rate impact on EPS guidance and continued vigilance on shipping, raw material, freight, and operational execution.

Key Analyst Questions & Responses: Analysts focused on pricing momentum into Q4 and fiscal 2027; management said pricing is now largely covering inflation and should show further sequential benefit in Q4, with steadier realization across segments and stronger flow-through next quarter. On manufacturing optimization and Hopewell, management said the biggest EBITDA recovery should start flowing in more meaningfully from Q2 of next year, with some benefits visible sooner but a quarter or two needed for full P&L impact. Analysts asked whether the Ancora agreement implied a formal sales process; management said no decision has been prescribed, and the new board members and capital allocation committee will review options while the core priority remains execution and value creation. Questions on Life Sciences sustainability were met with a full-year mid-single-digit growth outlook, supported by GLP-1 exposure, injectables, and launch momentum. Personal Care confidence was supported by broad-based volume growth, technology adoption, and pipeline conversion, not just destocking normalization.